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Abstract
Background: Familial Mediterranean fever (FMF) is one of the most frequent genetic diseases encountered in
the Mediterranean region. We aimed to investigate the correlation between genetic mutations and the
clinical findings in 562 patients with FMF.
Methods: In this retrospective cross-sectional study conducted with patients’ files between 2006, and 2013, reverse
hybridization assay for MEFV gene mutations was used and the 12 most frequent mutations were screened. Mutation
types and clinical findings were compared with variance analysis.
Results: The mean age was 6.9 ± 3.4 years (range, 1.8-11.6 years). The most common symptom was fever (97.3 %).
Thirty-four of the patients (6.04 %) were admitted with periodic fever only. Of these patients, M694V was the most
common mutation type (73.5 %). The percentage of the patients predominantly presenting with recurrent abdominal
pain was 77.78 % and the most frequent mutations were M694V and E148Q. The rate of arthritis and arthralgia was
significantly higher in patients with M694V and E148Q mutations. Chest pain was reported more often in patients
homozygous for M694V (61.4 %). Pericardial effusion was documented in the echocardiography of 10.9 % of the 229
children with chest pain. Some patients had both FMF and Henoch Schönlein purpura (HSP), and were more likely
to harbor either homozygote M694V or E148Q mutations. The frequency of episodes was higher in patients with
homozygous M694V mutations (number of attacks = 4.4 ± 1.6/month). Proteinuria was detected in 106 patients of
cases (29.2 %), at an average of 854 ± 145 mg/L. Most of the patients with proteinuria and elevated serum amyloid-A
had homozygous M694V mutation.
Conclusion: The most common mutation in children in Turkey with FMF is the M694V mutation. Recurrent
abdominal pain, arthritis or arthralgia, chest pain, and pericarditis were commonly seen in patients with
M694V and E148Q mutations.
Background
Familial Mediterranean Fever (FMF) is the most fre-
quent autoinflammatory disease in Turkey [1, 2]. It is
commonly seen among Turkish, Armenian, Arabic and
Sephardic Jewish populations [3].
The most noticable finding of the disease is painful
febrile episodes accompanied by peritonitis, pleuritic
pain or acute synovitis in many patients. Headache or
diffuse myalgia and malaise can also occur. The acute
phase reactants like serum amyloid A (SAA) are signifi-
cantly elevated [4, 5]. Recurrent orchitis and meningitis
are uncommon presentations.
To date, many mutations on the responsible pyrin
gene have been reported [6]. The pyrin gene was
mapped on the short arm of chromosome 16 and con-
tains approximately 60 kb sized genomic DNA [7].
In trials conducted in Turkish population, the most
common mutations were reported as M694V, E148Q,
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M680I and V726A [8]. The last ten years have seen
much research into the effect of particular genetic muta-
tions on clinical findings [9].
In this study, we aimed to investigate the correlation
between genetic mutations and clinical findings on ad-
mission of 562 patients with recurrent fever, abdominal
pain and/or arthritis/arthralgia and subsequently diag-
nosed as having FMF. The relationship between genetic
mutations, types and the severity of clinical findings in
patients who were diagnosed as having FMF were ana-
lyzed. Furthermore, the relationship between frequency
of proteinuria and genetic mutations were studied and
the effect of colchicine on SAA was demonstrated.
Methods
Study group
We conducted a retrospective cross-sectional study. Data
were transferred from the hospital software and patients’
files of patients who were admitted to Istanbul University,
Istanbul Medical Faculty, Department of General Pediatrics
between January 2006, and December 2013, with recurrent
fever, abdominal pain, and arthritis/arthralgia, and skin
eruptions.
A total of 1064 patients were admitted to our clinic
within this time period. Five hundred sixty-two children
(52.8 %) were diagnosed as having FMF and comprised
our study group. The age range of the study group was
1.8-16 years.
The diagnosis of FMF was established in accordance
with the Tel Hashomer Criteria [10] (Table 1). The
remaining patients who had been admitted to our clinic
were diagnosed as having infections (n = 292), allergic
diseases (n = 125), malignancy (n = 24), connective tissue
disease (n = 18), immunodeficiency syndromes (n = 13),
PFAPA (n = 26), cyclic neutropenia (n = 3), and hyper
IgD (n = 1) (Fig. 1).
An acute episode of FMF was diagnosed with fever that
lasted 1-3 days, accompanied by abdominal, chest, joint or
muscle pain, erysipelas like skin eruption, arthritis and
scrotal swelling, all of them disappearing spontaneously.
The patients’ clinical and laboratory evaluation results
were ‘normal’ between attacks. Severity of the disease
was determined in accordance with the criteria used
by Pras et al. [11]. (Table 2).
The patients who had HSP underwent skin biopsy and
immunoflorescence staining revealed deposition of IgA
and C3 along small vessels.
The study was ethically approved by the ethics comitee
within the Department of Pediatrics in our institution.
Written and verbal consent was obtained from parents
to use patient data for studies, but since this non-
interventional study only reports our experience with
patients managed according to the standard of care and
patients did not undergo any tests that were requested
solely for the purposes of obtaining data to include in
this study, no separate consent for enrollment in the
study was obtained.
Laboratory evaluations
SAA was measured in accordance with the manufacturer’s
instructions (Siemens Health Care Diagnostic Products
GmbH, Marburg/Germany) by N Latex SAA kits in
Behring Nephelometer Prospec machine. C-reactive pro-
tein (CRP) was quantified with immunoturbidimetric
methods as per the manufacturer’s instructions (Roche
Diagnostics GmbH, Sandhoffer Strasse, Mannheim/
Germany) by C-Reactive protein Latex kits (COBAS
INTEGRA/Cobas System) in Roche Hitachi Cobas C 501
analyzer.
The assay for proteinuria was a quantitative one based
on a 24 h urine collection. It was repeated one month
after initiation of treatment with colchicine.
Gene/mutation analysis
For 592 of the 1064 patients who reported fever, arthral-
gia and skin eruptions, autoinflammatory diseases were
considered as a diagnostic possibility and therefore, ana-
lysis of the pertinent gene mutations were ordered. 562
of these cases turned out to have mutations.
Patients provided 2 cc blood under appropriate clinical
conditions. DNA subtracts were taken from the blood
samples using a QIAamp DNA mini kit (QIAGEN, cata-
log no: 51306). An FMF Strip Assay (ViennaLab Labor-
diagnostika GmbH, Vienna, Austria) kit was used to
determine the presence of an Mediterranean fever
(MEFV) gene mutation in patients. For mutation ana-
lysis, exon 2 v 10 of the MEFV gene was amplified using
multiplex polymerase chain reaction (PCR) [12]. Ampli-
fied products were hybridized with oligonucleotide
probes. We screened for 12 MEFV gene mutations
Table 1 Tel-Hashomer diagnosis criteria [10]
Major criteria:
1-Recurrent febrile episodes associated with peritonitis, pleuritis or
synovitis
2-Amyloidosis of AA-type without a predisposing disease




3-Positive history of familial Mediterranean fever in a first degree
relative
Definite Diagnosis: The diagnosis if definite is 2 major or 1 major + 2 minor
criteria are met.
Probable diagnosis: The diagnosis is probable if 1 major + 1 minor
criterion are met.
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(E148Q in exon 2, P369S in exon 3, F479L in exon 5,
M680I [G/C], M680I [G/A], 1692del, M694v, M6941,
K695R, V726A, A744S, R761H in exon 10) using the FMF
Strip Assay, Vienna Lab Diagnostics GmbH, Vienna,
Austria. The mutations were called heterozygous, homo-
zygous, and compound heterozygous.
Genetic mutation analysis was performed in Istanbul
Medical Faculty Medical Biology laboratory. The white
blood cell number, CRP, fibrinogen, erythrocyte sedi-
mentation rate, SAA level, and protein amount in 24 h
urine were investigated in the patients’ febrile periods.
SAA level was also measured for a second time after
treatment with colchicine in order to screen whether
there was any influence with treatment.
Heterozygous patients were confirmed by sequence
analyses.
Exon 2, 3, 5 and 10 was sequenced by using GML Seq-
Finder Sequencing System MEFV kit with Sanger se-
quence technology. The PCR conditions were as follows:
Initial denaturation at 94 °C for 5 min, 35 cycles at 94 °C
for 30 s and 58 °C for 45 s, 72 °C for 1 min, and a final
extension at 72 °C for 5 min. The PCR products were
Fig. 1 The distribution of patients admitted with complaints of recurrent fever, abdominal pain, and arthritis/arthralgia and skin eruption
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visualized and collected with 2 % agarose gel electro-
phoresis, followed by purification using an Exo-SAP
PCR purification Kit (UAB Corporation Cleveland,
Ohio, USA). The product was sequenced in both
strands initiating from the forward and the reverse
primers used in the initial PCR and analysed on an
ABI 3130 Automated DNA Sequencer (Applied Bio-
systems, Foster City, CA, USA). Further analysis was
performed with SeqScape v2.6 and Sequencing Ana-
lysis 5.3.1 version programs [13].
Statistical analysis
All analyses were performed using SPSS 21.0. All con-
tinuous variables were examined using the paired or un-
paired t-test as appropriate. Non-continuous variables
were examined using the Chi-square test. The ratio of
mutation types and clinical findings were compared
with variance analysis. A P value < 0.05 for the two-
tailed t-test was considered statistically significant.
Results
Five hundred sixty-two children (52.8 %) were diagnosed
as having FMF among the 1064 patients who presented
with recurrent fever, abdominal pain, and arthritis/arth-
ralgia and skin eruption (Fig. 1).
Patients and clinical findings
Two hundred eighty-seven (51.0 %) of the study popula-
tion (n = 562) were female. The mean age was 6.9 ±
3.4 years (range, 1.8-11.6 years). The most common
symptom was fever (97.3 %, n = 547). The other frequent
symptoms were abdominal pain (543, 96.6 %) and arth-
ritis/arthralgia 243/358 (43.2 %/63.7 %). Moreover, skin
eruption was seen in 140 patients (24.9 %) and HSP was
found in 105 patients (18.6 %). The patients’ detailed
history and physical examination information are dem-
onstrated in Table 3.
Results of mutation analysis
The heterozygote mutation was positive in 252 patients
(44.8 %), homozygote mutations were positive in 228 pa-
tients (40.5 %), and compound heterozygote mutations
were positive in 82 patients (14.6 %). The total positivity
of mutations was as following: M694V (n = 290, 51.6 %),
E148Q (n = 114, 20.2 %), M680I (n = 64, 11.3 %), R202Q
(n = 57, 10.1 %), V726A (n = 18, 3.2 %), P369S (n = 9,
1.6 %), K695R (n = 7, 1.2 %) and U726A (n = 3, 0.5 %).
The most frequently seen mutations with sequence
analysis in heterozygote mutations were Met694Val
(n = 129, 51.1 %), pVal726Ala (n = 92, 36.5 %) and
pAla744Ser (n = 31, 12.4 %). The most frequently seen
mutations in compound heterozygote patients were
M694V/E148Q (n = 32 39 %).
The correlation of genetic mutations and symptoms
In total, 34 patients (6.04 %) were admitted with fever
only, and their mean age was 2.1 ± 0.1 years. Of these
Table 2 Pras et al. severity scoring system for pediatric FMF [11]
Variable Score
Appearing of disease (year) >11 2
6-10 3
<6 4
Frequency of attack on admission <1 1
1-2 2
>2 3
Severity of arthritis Acute 2
Degenerative 3
Erysipelas-like erythema present 3




Note: Score 3-5 Mild; 6-8 moderate; >9 severe disease. anon-response
to colchicine
Table 3 The past medical history, response to colchicine,







FMF in family history 251 44.6
Appendectomy history 26 4. 6
Findings
Fever 547 97.3
Abdominal pain 543 96.6
Arthralgia 358 63.7
Arthritis 243 43.2
Chest pain 229 40.7
Skin eruption 140 24.9
Henoch-Schonlein Purpura 105 18.6







Compound heterozygote 82 14.7
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patients, M694V was detected in 25 patients and R202Q
homozygous mutation was found in 9 patients. The
response to colchicine of all these patients was favorable.
Twenty-seven patients (4.8 %) who had no fever pre-
sented only with abdominal pain and their mean age
was 4.5 ± 0.4 years. Among these patients, M694V was
found in 20 patients and E148Q homozygote mutation
was determined in 7 patients. The mean age of patients
who were admitted with abdominal pain alone was
significantly higher than those who presented only with
fever (p = 0.04). Abdominal pain was significantly more
frequent in patients with M694V and E148Q heterozy-
gote mutation than in children with R202Q and M680I
heterozygous mutations (p = 0.012).
228 of the 228 homozygous patients, 206 of the 252
heterozygous patients and 64 of the 82 compound het-
erozygous patients had their disease severity scored and
evaluated to see if there are statistically significant differ-
ences depending on the type of mutation (Table 4).
The percentage of the clinically severe homozygote
M694V mutations was 24.1 % (n = 70). This percentage
was significantly higher than other homozygote muta-
tions (p < 0.01).
Arthritis/arthralgia was significantly more common in
patients with M694V and E148Q homozygous mutations
(p = 0.014, p = 0.01, respectively).
Chest pain was more frequent in homozygous M694V
(61,4 %) and heterozygous E148Q (25.6 %) mutation types
(p = 0.04). Pericardial effusion was observed using echo-
cardiography in 25 (10.9 %) of the 229 children with chest
pain. The chest pain was unresponsive to colchicine in
eight of these patients, consequently they were treated
with methylprednisolone.
Skin eruptions were most commonly seen in homozy-
gous E148Q mutations (p = 0.04). This was followed by
heterozygous M694V and heterozygous M680I mutations.
Homozygous M694V (n = 34, 32.3 %) and homozygous
E148Q (n = 23, 22 %) mutations were significantly more
common in patients who also had HSP (p = 0.03). De-
tailed clinical findings and mutation analysis information
are shown in Table 5.
The most common febrile episodes were in patients
with M694V homozygous mutations (number of attacks =
4.4 ± 1.6/month). This was followed by compound het-
erozygous M694V-M680I mutations (number of at-
tacks = 3.6 ± 1.1/month) and M680I-E148Q mutations
(number of attacks = 2.3 ± 1.1/month).
Fever (n = 30), abdominal pain (n = 32), arthritis (n = 17)
and arthralgia (n = 24) were the most common symptoms
in compound heterozygous M694V-E148Q mutations.
The patients with compound heterozygous M694V/
R202Q (n = 30, 36.5 %) mutations had skin eruptions
(n = 16, 53.3 %) and HSP (n = 14, 36.6 %) in addition
to fever and abdominal pain.
Patients with a history of appendectomy (n = 26) car-
ried M694V homozygous mutations (n = 16) and E148Q
homozygous mutation (n = 10).
Some of (n = 12, 2.29 %) the colchicine responsive pa-
tients (n = 524) had diarrhea after one week. We reduced
the dose and continued the therapy.
Table 4 The distribution of severity of FMF according to genetic mutations and types (n:562)
Homozygote mutations (n: 228; 40.5 %)
M694V E148Q M680I R202Q V726A P369S K695R U726A
Mild 17 23 4 13 3
Moderate 27 14 12 14 1
Severe 70 12 10 6 2
Total 114 49 26 33 6
Heterozygote mutations (n: 252; 44.8 %)
M694V E148Q M680I R202Q V726A P369S K695R U726A
Mild 41 10 6 3 1 9 7 3
Moderate 57 9 8 4 2
Severe 22 6 12 5 1
Total 120 25 26 12 4 9 7 3
Compound Heterozygote mutations (n: 82; 14.6 %)
M694V/E148Q M694V/R202Q M694V/M680I E148Q/V726A
Mild 12 3 1 5
Moderate 15 2 2 3
Severe 5 7 9
Total 32 12 12 8
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There was no difference in the clinical features and
genotypes of the cases required hospitalization and those
that were managed as outpatients. The M694 mutation
was prevalent in both groups.
Laboratory evaluations
The mean level of leucocytes was 17 580 ± 5571 mm3
(range, 5100-29 700) on admission and C-reactive pro-
tein was 64 ± 32.42 mg/dL (range, 6-245 mg/dL),
erythrocyte sedimentation rate was 74.47 ± 32.24 mm/h
(range, 8-132 mm/h), and fibrinogen was 463.24 ±
70.50 mg/dL (range, 298-875 mg/dL). Proteinuria was
also detected in 106 patients (29.2 %) at an average of
854 ± 145 mg/L (Table 6). One month after initiation of
treatment with colchicine, protein excretion at the end of
the treatment month was found to be 236 ± 14.5 mg/dL,
which was significantly lower (p < 0.05)
Among the patients with proteinuria, homozygous
M694V mutations were determined in 75 patients, homo-
zygous M680I was in 12, homozygous E202Q was in 9,
homozygous E148Q was in 6 patients, and other muta-
tions were detected in 4 patients.
The mean level of SAA on admission was 222.4 ±
100.0 mg/dL. This was found as 388.3 ± 35.6 in children
with homozygote M694V mutations. This suggested that
the SAA level in homozygous M694V mutation was sig-
nificantly higher than in other mutations (Table 7).
Moreover, all patients with homozygous mutations had
higher levels of SAA compared with children with hetero-
zygous and compound heterozygous mutations (p = 0.02
and p = 0.03, respectively). Patients who had a complete
response to monthly colchicine therapy (n = 524) had an
average 11.18 ± 2.6 mg/dL SAA level after treatment and
there was no difference between mutation types.
Patients who had a partial response to monthly colchi-
cine therapy (n = 38) had an average 156.34 ± 23.4 mg/dL
SAA level. The level of SAA was significantly lower in
complete responsive than in partial responsive (p = 0.001).
Discussion
In this study we aimed to screen the correlation between
genetic and phenotype of Turkish children who had
Table 5 The correlation of clinical findings and mutation types in patients with FMF (n:562)








547 543 358 243 229 105 140 524 38
n/% n/% n/% n/% n/% n/% n/% n/% n/%
M694V (290/562) 290/53 290/53.4 142/39.6 87/35.8 175/76.4 55/52.3 37/26.4 282/53.8 15/39.5
E148Q (114/562) 110/21.5 104/19.1 113/31.5 96/39.5 44/19.2 38/36.1 60/42.8 112/21.3 6/15.8
M680I (64/562) 60/10.9 62/11.4 40/11.1 35/14.4 8/3.4 7/6.6 21/15 59/11.2 12/31.5
R202Q (57/562) 55/10 55/10.1 47/13.1 18/7.4 2/0.8 5/4.7 5/3.5 55/10.4 5/13.2
V726A (18/562) 18/3.2 18/3.3 10/2.7 2/0.8 - - 8/5.7 10/1.9 -
P369S (9/562) 9/1.6 8/1.4 3/0.8 2/0.8 - - 9/6.4 2/0.3 -
K695R (7/562) 7/1.42 5/0.9 2/0.5 1/0.4 - - - 2/0.3 -
U726A (3/562) 1/0.1 1/0.1 1/0.2 1/0.4 - - - 2/0.3 -
M694V/R202Q (30/562) 30/5.5 30/5.5 11/3.1 18/7.4 11/4.8 14/13.3 16/11.4 30/5.7 -
M694V/E148Q (32/562) 30/5.5 32/5.9 24/6.7 17/7.0 12/5.2 6/5.7 8/5.7 32/6.1
M694V/ M680I (12/562) 12/2.2 12/2.2 10/2.8 2/0.8 4/1.7 - 8/5.7 12/2.3 -
E148Q/V726A (8/562) 8/1.5 5/0.9 3/0.8 1/0.4 4/1.7 5/4.8 - 8/1.5 -
Table 6 Laboratory evaluations of patients with FMF
Variable Mean ± SDS Min-Max
Age (years) 8.58 ± 4.2 1 – 16
Leucocyte /mm 3 17.580 ± 5.571 5100 - 29700
CRP (mg/dL) 64.5 ± 32.42 6 - 245
ESR(mm/saat) 74.47 ± 32.24 8 - 132
Fibrinogen(mg/dL) 463.24 ± 70.50 298 - 875
Proteinuria (mg/L) 854 ± 145 520 - 2410
(positive in 106 patients)
Table 7 The response to colchicine therapy and serum level of
SAA
The response to colchicine therapy




Mean ± SD mg/dL Mean ± SD mg/dL
Homozygous 234.2 ± 22.3 14.1 ± 1.4
Heterozygous 154.3 ± 13.8 12.2 ± 1.3
Compound Heterozygous 182.1 ± 12.4 13.3 ± 1.2
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been diagnosed as having FMF. Therefore, we investi-
gated the 12 most frequent mutations and concomitant
clinical and laboratory findings. The frequency of FMF
among patients who were admitted with recurrent fever,
abdominal pain, and arthritis/arthralgia and skin erup-
tions was 53.6 %. This result was similar to the study
conducted by Ulgenalp et al. (50.5 %) [14].
The most common symptom was fever (97.3 %). The
other frequent symptoms were abdominal pain (96.6 %)
and arthritis/arthralgia (43.2 %/63.7 %). These clinical
findings were mostly accompanied by M694V homozy-
gous/heterozygous mutations. Similar to other studies,
the most commonly seen mutation that accompanied
clinical findings was M694V. Özelkaya et al. showed that
the most frequent symptoms were abdominal pain
(83.1 %) and fever (55 %). Other common findings re-
ported are arthritis (17.1 %) and erysipelas-like erythema
(7.7 %). It was also demonstrated that these clinical find-
ings were mostly accompanied by M694V homozygote
mutations [15–17].
Solak et al. reported the most common symptom to be
abdominal pain, which was followed by fever, arthralgia,
chest pain, and skin eruptions in a study of 165 patients.
In this study, the most commonly seen mutations were
M694V/I, E148Q and M680I [18]. Akar et al. reported
that the most frequent mutations were M694V and
M680I [19]. Giancane et al. reported that the E148Q
variant is common, of unknown pathogenic significance
and as the only MEFV variant does not support the diag-
nosis of FMF [20].
In our study, distinct from other studies, E148Q was
the second most common mutation that accompanied
fever, arthritis, and arthralgia. M680I was the third most
common mutation and was found less frequently in
patients with arthralgia/arthritis, but was seen more
frquently in patients with skin eruptions.
Chest pain was most frequently seen in patients with
M694V homozygous and E148Q heterozygous muta-
tions. Similar to other studies, the M694V was the most
commonly determined mutation in these patients.
Marek et al. researched the second other mutation
apart from 12 mutations in patients with heterozy-
gous MEFV gene mutations and demonstrated the
second mutation in 25 % of patients [21]. We did
not investigate second analysis in patients with het-
erozygous mutations.
The mean age of patients who only had fever on
admission was significantly lower than patients who pre-
sented with abdominal pain alone. It has been reported
that fever is a common finding in younger patients; how-
ever, serositis, skin eruptions and other findings are
more often seen in older patients with FMF [22]. Padeh
et al. also stated that the first symptom of the disease
might be fever and serositis may develop later in the
course [23]. MEFV gene mutations can be found in pa-
tients with HSP. FMF has been reported more frequently
in patients who had HSP than in the general population.
MEFV mutations may be related to HSP susceptibility in
children [24]. Salah et al. found heterozygous mutations
of V726A and E148Q to be the most common in chil-
dren who also had HSP [25]. In contrast, we found
homozygous mutations of M694V and E148Q to be the
most common. Dogan et al. found that 11 of their 76
patients (14.4 %) were heterozygous, and 5 patients
(6.6 %) were homozygous and 2 were compound hetero-
zygous [26]. Altug et al., found that 18 of their 68
patients with HSP had MEFV mutations, 15 of them
being heterozygous [27].
Our study included more patients who were first diag-
nosed with FMF and later went on to have HSP. This
could be the reason why our study had more homozy-
gous mutations in contrast to the findings of the three
studies mentioned above [27].
In our study, in patients who had been previously
diagnosed as having FMF and presented with findings
pertinent to HSP, we found that the most common mu-
tation of the 105 patients was M694V (n = 55, 52.3 %);
the second most common was E148Q (n = 28, 26.6 %).
Homozygous M694V and E148Q mutations were par-
ticularly common (p = 0.03).
FMF strip assay is a fast screening test; the most com-
mon major 12 mutations with known clinical meaning
can be investigated. Screening can investigate only 12
mutations, whereas sequencing gives a result of all
changes of exons 2,3,5 and 10 on MEFV gene that can
be reviewed. More detailed sequencing tehcniques can
reveal that clinically diagnosed patients who had none of
the 12 most common mutations may actually have some
of the less common mutations or novel mutations.
Proteinuria was reported to be positive most com-
monly with the M694V mutation and less frequent with
E148Q [28].
Serum Amyloid A levels on admission with homozy-
gous M694V mutation were significantly higher than
with other mutations such as heterozygous and com-
pound heterozygous mutations. Similar to the study of
Berkun et al., the SAA level was higher in patients with
homozygous M694V mutation [29]. According to a
study conducted by Duzova et al., SAA was higher with
homozygous and compound heterozygous mutations
[30]. There was no significant difference in SAA level
between mutation types in children with complete
response. The level of SAA was significantly lower in
patients who were completely responsive to colchicine
than in partially responsive patients [31]. Similar to our
study, the authors emphasized that administration of
colchicine might be effective in diminishing the SAA
level [31]. In our study, we showed a decrease in level of
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SAA in patients who had a complete response to colchi-
cine therapy. The dose of colchicine was not increased.
A retrospective case series review was conducted of all
MEFV gene mutation testing completed at UCLA Clin-
ical Molecular Diagnostic Laboratory by Ong et al. to
correlate specific genotypes with adverse phenotypes of
affected populations residing in the Western United
States, between February 2002, and February 2012. This
was followed by a clinical chart review of all subjects
who either had a single or double mutation. All 12 com-
mon mutations in the MEFV gene were analyzed and
the M694V variant was found to be associated with an
adverse FMF clinical outcome in the Armenian-
American population, which manifested as earlier onset
of disease, increased severity of disease, and renal amyl-
oidosis [32].
In our study, M694V was found to be the most com-
mon mutation and it heralds more proteinuria and a
more severe clinical course.
Conclusion
In summary, the frequency of FMF was 52.8 %. Fever
was the most frequent symptom. The most common
mutation was M694V. The mean age of patients who
were admitted with abdominal pain alone was signifi-
cantly higher than patients who presented with fever
alone. Abdominal pain was significantly more frequent
in patients with M694V and E148Q heterozygous muta-
tions than children with R202Q and M680I heterozy-
gous mutations. Arthritis/arthralgia were significantly
more common in patients with homozygous M694V and
E148Q mutations. Chest pain was more frequent with
homozygous M694V (61.4 %) and heterozygous E148Q
(25.6 %) mutations (p = 0.04). In 25 of the 229 children
(10.9 %) with chest pain, pericardial effusion was docu-
mented at echocardiography. Skin eruption was most
commonly seen in homozygous E148Q mutations. This
was followed by heterozygous M694V and heterozygous
M680I mutations. Homozygous M694V (n = 34, 32.3 %)
and E148Q (n = 23, 22 %) mutations were significantly
more frequent in patients with HSP (p = 0.03). Arthritis
(n = 17, 7.0 %) and arthralgia (n = 24, 6.7 %) were seen
more frequently in patients with compound heterozy-
gous M694V/E148Q mutations, whereas M694V/R202Q
coexistence caused skin eruptions (n = 16, 11.4 %) more
frequently. The most frequent occurence of febrile epi-
sodes were in patients with M694V homozygous muta-
tions (number of attacks = 4.4 ± 1.6/month). Patients
with a history of appendectomy (n = 26) carried homozy-
gous M694V (n = 16) and E148Q (n = 10) mutations.
Diarrhea developed after colchicine therapy in 0.22 % of
patients. The ratio of the clinically-severe patients was
24.1 % (n = 70) in children with homozygous M694V
mutations. This ratio was significantly higher than other
homozygous mutations. Proteinuria was detected most
frequently in patients with homozygous M694V muta-
tions. The SAA level in homozygous M694V mutations
was significantly higher than in other mutations.
Our study was comprehensive and has demonstrated
the correlation between the genotype and the clinical
characteristics of FMF in Turkish children. Patients were
classified and analyzed according to clinical, laboratory,
and genotype features. However, a major limitation of
our study is its retrospective design and the lack of a
demographic analysis due to insufficient information
about the place of birth of the patients.
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